(NASDAQ: GLYC) Glycomimetics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Glycomimetics's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast GLYC's revenue for 2025 to be $1,526,121,068, with the lowest GLYC revenue forecast at $109,468,600, and the highest GLYC revenue forecast at $2,942,773,536. On average, 1 Wall Street analysts forecast GLYC's revenue for 2026 to be $824,234,163, with the lowest GLYC revenue forecast at $824,234,163, and the highest GLYC revenue forecast at $824,234,163.
In 2027, GLYC is forecast to generate $1,732,179,609 in revenue, with the lowest revenue forecast at $1,732,179,609 and the highest revenue forecast at $1,732,179,609.